Dezerv

Fund Overview

Fund Size

Fund Size

₹7,125 Cr

Expense Ratio

Expense Ratio

1.83%

ISIN

ISIN

INF204K01968

Minimum SIP

Minimum SIP

₹1,000

Exit Load

Exit Load

1.00%

Inception Date

Inception Date

05 Jun 2004

About this fund

Nippon India Pharma Fund Regular Growth is a Sector - Healthcare mutual fund schemes offered by Nippon India Mutual Fund. This fund has been in existence for 19 years, 10 months and 12 days, having been launched on 05-Jun-04.
As of 16-Apr-24, it has a Net Asset Value (NAV) of ₹423.86, Assets Under Management (AUM) of 7125.28 Crores, and an expense ratio of 1.83%.
  • Nippon India Pharma Fund Regular Growth has given a CAGR return of 20.76% since inception.
  • The fund's asset allocation comprises around 97.16% in equities, 0.00% in debts, and 2.84% in cash & cash equivalents.
  • You can start investing in Nippon India Pharma Fund Regular Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+51.36%

+49.84%(Cat. Avg.)

3 Years

+16.45%

+15.80%(Cat. Avg.)

5 Years

+22.49%

+22.24%(Cat. Avg.)

10 Years

+17.10%

+16.14%(Cat. Avg.)

Since Inception

+20.76%

--%(Cat. Avg.)

Portfolio Summaryas of 31st March 2024

Equity6,922.76 Cr97.16%
Others202.52 Cr2.84%

Top Holdings

All Holdings

Equity

Debt & Others

NameType sortAmount sortHoldings sort
Sun Pharmaceuticals Industries LtdEquity1,062.49 Cr14.91%
Lupin LtdEquity598.81 Cr8.40%
Cipla LtdEquity464.05 Cr6.51%
Apollo Hospitals Enterprise LtdEquity412.43 Cr5.79%
Dr Reddy's Laboratories LtdEquity338.7 Cr4.75%
Gland Pharma LtdEquity313.69 Cr4.40%
Divi's Laboratories LtdEquity310.36 Cr4.36%
Zydus Lifesciences LtdEquity297.53 Cr4.18%
J.B. Chemicals & Pharmaceuticals LtdEquity245.39 Cr3.44%
Abbott India LtdEquity234.3 Cr3.29%
Ajanta Pharma LtdEquity215.99 Cr3.03%
Medplus Health Services LtdEquity211.62 Cr2.97%
Mankind Pharma LtdEquity207.25 Cr2.91%
Vijaya Diagnostic Centre LtdEquity201.24 Cr2.82%
Aurobindo Pharma LtdEquity196.06 Cr2.75%
Narayana Hrudayalaya LtdEquity192.73 Cr2.70%
Sanofi India LtdEquity191.5 Cr2.69%
Alkem Laboratories LtdEquity186.52 Cr2.62%
GlaxoSmithKline Pharmaceuticals LtdEquity166.22 Cr2.33%
Torrent Pharmaceuticals LtdEquity156.91 Cr2.20%
Pfizer LtdEquity133.5 Cr1.87%
Fortis Healthcare LtdEquity117.66 Cr1.65%
Triparty RepoCash - Repurchase Agreement112.24 Cr1.58%
Thyrocare Technologies LtdEquity104.18 Cr1.46%
Nippon India Liquid Dir GrMutual Fund - Open End100.15 Cr1.41%
Syngene International LtdEquity79.02 Cr1.11%
Orchid Pharma LtdEquity75.55 Cr1.06%
Indoco Remedies LtdEquity60.3 Cr0.85%
Concord Biotech LtdEquity38.2 Cr0.54%
Metropolis Healthcare LtdEquity36 Cr0.51%
AstraZeneca Pharma India LtdEquity34.14 Cr0.48%
Jubilant Pharmova LtdEquity26.89 Cr0.38%
HealthCare Global Enterprises LtdEquity13.53 Cr0.19%
Net Current AssetsCash-9.95 Cr0.14%
Cash Margin - CcilCash - Collateral0.08 Cr0.00%

Allocation By Market Cap (Equity)

Large Cap Stocks

41.43%

Mid Cap Stocks

33.14%

Small Cap Stocks

22.58%

Other Allocation

Equity Sector

Debt & Others

SectorAmount sortHoldings sort
Healthcare6,922.76 Cr97.16%

Risk & Performance Ratios

Standard Deviation

This fund

15.51%

Cat. avg.

15.23%

Lower the better

Sharpe Ratio

This fund

0.91

Cat. avg.

0.85

Higher the better

Sortino Ratio

This fund

--

Cat. avg.

1.50

Higher the better

Fund Managers

SR

Sailesh Raj Bhan

Since April 2005

KD

Kinjal Desai

Since May 2018

Additional Scheme Detailsas of 31st March 2024

ISININF204K01968Expense Ratio1.83%Exit Load1.00%Fund Size₹7,125 CrAge05 Jun 2004Lumpsum Minimum₹5,000Fund StatusOpen Ended Investment CompanyBenchmarkS&P BSE Healthcare TR INR

Investment ObjectiveInvestment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Withdrawal within 1 year

Flat 15% tax on realised gains (STCG - short term capital gains)

Withdrawal after 1 year

10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)

Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund nameExpense RatioExit LoadFund size
1Y
Motilal Oswal S&P BSE Healthcare ETF

Very High Risk

0.2%-₹12.94 Cr54.2%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Very High Risk

1.0%1.0%₹699.55 Cr56.4%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹699.55 Cr54.3%
Aditya Birla Sun Life Nifty Healthcare ETF

Very High Risk

0.2%-₹39.74 Cr51.4%
ITI Pharma and Healthcare Fund Direct Growth

Very High Risk

0.4%1.0%₹160.39 Cr49.8%
ITI Pharma and Healthcare Fund Regular Growth

Very High Risk

2.3%1.0%₹160.39 Cr46.7%
Mirae Asset Healthcare Fund Direct Growth

Very High Risk

0.5%1.0%₹2235.15 Cr49.9%
Mirae Asset Healthcare Fund Regular Growth

Very High Risk

2.0%1.0%₹2235.15 Cr47.7%
Nippon India Nifty Pharma ETF

Very High Risk

0.2%-₹643.07 Cr50.6%
Axis NIFTY Healthcare ETF

Very High Risk

0.3%-₹16.53 Cr50.3%

About the AMC

Total AUM

₹4,42,327 Cr

Address

4th Floor, Tower A, Peninsula Business Park, Mumbai, 400 013

Other Funds by Nippon India Mutual Fund

Fund nameExpense RatioExit LoadFund size
1Y
Nippon India Fixed Maturity Plan - XLVI - Series 1 - 92 Days Direct Growth

Moderately High risk

-0.0%--
Nippon India Innovation Fund Direct Growth

Very High Risk

0.9%1.0%₹1354.69 Cr-
Nippon India Fixed Horizon Fund XLII Series 1 Direct Growth

Moderate Risk

----
Nippon India Fixed Horizon Fund XLII Series 7 Direct Growth

Moderate Risk

----
Nippon India Fixed Horizon Fund XLI Series 6 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund XLII Series 5 Direct Growth

Moderate Risk

----
Nippon India Fixed Horizon Fund XLI Series 7 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund - XLIII - Series 4 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund XLII Series 6 Direct Growth

Moderate Risk

----
Nippon India Interval Fund Quarterly Series I Direct Growth

Moderate Risk

-0.0%₹52.30 Cr7.1%
Nippon India Fixed Horizon Fund XXXX Series 10 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund XLIV Series 4 Direct Growth

Low to Moderate Risk

---7.2%
Nippon India Fixed Horizon Fund XLIV Series 3 Direct Growth

Moderate Risk

----
Nippon India Interval Fund Annual Series I Direct Growth

Low Risk

-0.0%₹16.36 Cr7.2%
Nippon India Fixed Horizon Fund XLIV Series 5 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund - XLIII - Series 1 Direct Growth

Low to Moderate Risk

-0.0%₹186.11 Cr7.1%
Nippon India Fixed Horizon Fund XLIV Series 1 Direct Growth

Moderate Risk

-0.0%-7.0%
Nippon India Fixed Horizon Fund - XLIII - Series 3 Direct Growth

Moderate Risk

----
Nippon India Fixed Horizon Fund XLI Series 5 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund XLII Series 3 Direct Growth

Moderate Risk

----
Nippon India Fixed Horizon Fund XLIII Series 5 Direct Growth

Moderate Risk

-0.0%₹159.50 Cr7.5%
Nippon India Fixed Horizon Fund XXXIX Series 12 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund - XLIII - Series 2 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund XLI Series 3 Direct Growth

Moderate Risk

-0.0%--
Nippon India Capital Protection Oriented Fund II Plan A Direct Growth

Low Risk

--₹40.32 Cr9.7%
Nippon India Interval Fund Quarterly Series III Direct Growth

Low Risk

-0.0%₹4.92 Cr7.2%
Nippon India Fixed Horizon Fund XLI Series 13 Direct Growth

Moderate Risk

----
Nippon India Fixed Horizon Fund XXXX Series 9 Direct Growth

Moderate Risk

-0.0%--
Nippon India Interval Fund Quarterly Series II Direct Growth

Moderate Risk

-0.0%₹82.89 Cr7.5%
Nippon India Fixed Horizon Fund XXXX Series 18 Direct Growth

Moderate Risk

-0.0%--
Nippon India Interval Fund Monthly Series II Direct Growth

Low Risk

-0.0%₹3.93 Cr6.5%
Nippon India Fixed Horizon Fund XXXX Sr 20 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund - XXXX Series 13 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund - XLV - Series 4 Direct Growth

Low to Moderate Risk

-0.0%-7.2%
Nippon India Fixed Horizon Fund XLI Series 9 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund XLI Series 8 Direct Growth

Moderate Risk

-0.0%₹58.87 Cr7.5%
Nippon India Interval Fund Monthly Series I Direct Growth

Low Risk

-0.0%₹3.21 Cr6.4%
Nippon India Fixed Horizon Fund - XLV - Series 5 Direct Growth

Moderately High risk

-0.0%-9.1%
Nippon India Fixed Horizon Fund XXXIX Series 13 Direct Growth

Moderate Risk

-0.0%--
Nippon India Fixed Horizon Fund XLII Series 2 Direct Growth

Moderate Risk

----
Nippon India Nifty SDL Plus G-Sec - Jun 2029 Maturity 70:30 Index Fund Direct Growth

Moderate Risk

0.2%0.0%₹294.42 Cr7.2%
Nippon India Arbitrage Fund Direct Growth

Low Risk

0.4%0.0%₹13895.86 Cr8.5%
Nippon India Gilt Securities Fund Direct Growth

Moderate Risk

0.6%0.0%₹1546.55 Cr7.5%
Nippon India Banking & Financial Services Fund Direct Growth

Very High Risk

1.1%1.0%₹5307.29 Cr31.6%
Nippon India Power & Infra Fund Direct Growth

Very High Risk

1.1%1.0%₹4528.93 Cr77.3%
Nippon India Dynamic Bond Fund Direct Growth

Moderate Risk

0.3%0.0%₹4559.36 Cr7.4%
Nippon India Growth Fund Direct Growth

Very High Risk

0.8%1.0%₹24796.00 Cr57.0%
Nippon India Multi Cap Fund Direct Growth

Very High Risk

0.8%1.0%₹27745.59 Cr51.7%
Nippon India Gold Savings Fund Direct Growth

High Risk

0.9%1.0%₹1709.27 Cr19.0%
Nippon India Floating Rate Fund Direct Growth

Moderate Risk

0.3%0.0%₹7942.80 Cr7.8%

Risk Level

Your principal amount will be at Very High Risk

Very High Risk
Wealth Monitor

Unlock Expert Insights!

Maximise Returns with our Wealth Monitor App. Try it now!

Still got questions?
We're here to help.

The NAV of Nippon India Pharma Fund Regular Growth, as of 16-Apr-2024, is ₹423.86.
The fund has generated 51.36% over the last 1 year and 16.45% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.
The fund's allocation of assets is distributed as 97.16% in equities, 0.00% in bonds, and 2.84% in cash and cash equivalents.
The fund managers responsible for Nippon India Pharma Fund Regular Growth are:-
  1. Sailesh Raj Bhan
  2. Kinjal Desai